London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
For those looking into Investing, you may not realise that with a de-merger soon of our world class StemprintER, you will automatically receive 1 share for every 1 share you hold in Tils at a record date shortly to be advised,
This still leaves a number of world class products in Tils.
Also note that StemprintER has to-date no value in Tils share price as it was totally overlooked until recently.
You will effectively get 2 companies with world class products that should be valued in the Billions .
$3b for StemprintER and £10b for Tils.
Gla,
vbw
Regeneron halts one phase III COVID-19 trial while starting two others
July 6, 2020
By Lee Landenberger
Missing the primary endpoint along with key secondary endpoints in a phase III trial of Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, for treating COVID-19 patients who need mechanical ventilation caused Regeneron Pharmaceuticals Inc. and Sanofi SA to halt the study.
Tarrytown, N.Y.-based Regeneron then followed the closing by initiating two late-stage studies, a phase III and a phase II/III, to evaluate REGN-CoV2, a double antibody ****tail for treating and preventing COVID-19.
The stumble produced a good day for Tiziana Life Sciences plc (NASDAQ:TLSA), whose stock rose 9.6% July 6, closing at $7.19 a share. London-based Tiziana is developing its own anti-IL-6 receptor monoclonal antibody, TZLS-501, to be delivered directly into the lungs of a COVID-19 patient using an inhaler or nebulizer. In April, the company filed a patent application to support the treatment.
H.C. Wainwright and Co. analyst Raghuram Selvaraju wrote Monday morning that he believes “TZLS-501 may prove successful where Kevzara failed.” He also noted that TZLS-501 may also demonstrate superior efficacy to Actemra (tocilizumab) from Roche Holding AG, which is in late-stage development for treating coronavirus patients and is also being tested in combination with Gilead Sciences Inc.’s remdesivir.
“TZLS-501, a unique and best-in-class anti-IL-6R mAb, follows a dual mechanism by not only blocking downstream signaling pathways from membrane-bound and soluble IL-6 receptors but also rapidly depleting bloodstream (i.e., systemic) levels” of IL-6, Selvaraju added.
The study of Kevzara, a drug usually prescribed for treating rheumatoid arthritis, had problems before this halt. The study was amended in late April after an independent data monitoring committee reviewed all the available phase II and phase III data and found that, compared to placebo, the treatment “had no notable benefit on clinical outcomes” in patients with severe or critical respiratory illness caused by COVID-19. The study was tweaked immediately afterward so that only critically ill COVID-19 patients would be enrolled to receive Kevzara or placebo.
In the amended study results, there were some minor positive trends noted in the primary prespecified analysis group, which were critical patients receiving Kevzara 400 mg and were mechanically ventilated at baseline, that failed to reach statistical significance. However, negative trends in the subgroup of critical patients not mechanically ventilated at baseline countered the positive ones.
The trial’s primary analysis group included 194 patients who were critically ill with COVID-19 and receiving mechanical ventilation at the time they were enrolled. The primary endpoint was an assessment of patients achieving at least a one-point change, on a seven-point scale, from baseline. The scale included death; those hospitalized requ